ULTI Stock Overview
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Ultimovacs ASA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr7.97 |
52 Week High | kr178.60 |
52 Week Low | kr6.07 |
Beta | 1.16 |
1 Month Change | -94.09% |
3 Month Change | -93.51% |
1 Year Change | -93.01% |
3 Year Change | -87.47% |
5 Year Change | n/a |
Change since IPO | -74.29% |
Recent News & Updates
Recent updates
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth
Feb 21Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business
Oct 26Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth
Oct 05Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans
May 19Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation
Jul 27We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely
Mar 23Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?
Feb 13Insider Buying: The Ultimovacs ASA (OB:ULTI) Chief Executive Officer Just Bought 12% More Shares
Jan 14Shareholder Returns
ULTI | NO Biotechs | NO Market | |
---|---|---|---|
7D | 25.9% | 2.6% | 1.2% |
1Y | -93.0% | -68.7% | 4.1% |
Return vs Industry: ULTI underperformed the Norwegian Biotechs industry which returned -68.7% over the past year.
Return vs Market: ULTI underperformed the Norwegian Market which returned 5.4% over the past year.
Price Volatility
ULTI volatility | |
---|---|
ULTI Average Weekly Movement | 28.3% |
Biotechs Industry Average Movement | 9.3% |
Market Average Movement | 5.3% |
10% most volatile stocks in NO Market | 10.3% |
10% least volatile stocks in NO Market | 2.8% |
Stable Share Price: ULTI's share price has been volatile over the past 3 months.
Volatility Over Time: ULTI's weekly volatility has increased from 17% to 28% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 24 | Carlos de Sousa | https://ultimovacs.com |
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Ultimovacs ASA Fundamentals Summary
ULTI fundamental statistics | |
---|---|
Market cap | kr274.22m |
Earnings (TTM) | -kr189.24m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs ULTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ULTI income statement (TTM) | |
---|---|
Revenue | kr0 |
Cost of Revenue | kr0 |
Gross Profit | kr0 |
Other Expenses | kr189.24m |
Earnings | -kr189.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
Earnings per share (EPS) | -5.50 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did ULTI perform over the long term?
See historical performance and comparison